1. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set 
Christopher Ma, Remo Panaccione, Richard N. Fedorak, Claire E. Parker, Tran M. Nguyen, Reena Khanna, Corey A. Siegel, Laurent Peyrin-Biroulet, Geert D’Haens, William J. Sandborn, Brian G. Feagan, Vipul Jairath 
Clinical Gastroenterology and Hepatology 
Volume 16, Issue 5, Pages e13 (May 2018)
DOI: /j.cgh
Copyright © 2018 AGA Institute Terms and Conditions

2. Figure 1
Flow diagram for assessment of trials identified by the search strategy. RCT, randomized controlled trial; UCDAI, Ulcerative Colitis Disease Activity Index.
Clinical Gastroenterology and Hepatology  , e13DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

3. Figure 2
Proportion of placebo-controlled ulcerative colitis trials reporting key efficacy and safety outcome domains, stratified by decade of publication.
Clinical Gastroenterology and Hepatology  , e13DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

4. Figure 3
Outcome reporting matrix for placebo-controlled ulcerative colitis trials.
Clinical Gastroenterology and Hepatology  , e13DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions